The Mayo Clinic, through the vehicle of the North Central Cancer Treatment Group (NCCTG) and, increasingly, through the Alliance for Clinical Trials in Oncology (aka, Alliance or ACTION), will serve as a primary research base for the 34 CCOPs with current NCCTG affiliations, providing both treatment and cancer control trials. We will also serve as a research base for cancer control and treatment protocol activity of non-CCOP members of the NCCTG. We will cooperate with our affiliated CCOPs and other members in conducting appropriate continuing education and workshops. The research base will provide training and active support for their data managers/research associates and oncology nurses. We will coordinate their multidisciplinary involvement in clinical cancer research protocols. By group meetings involving NCCTG and Alliance members, we will facilitate the review of ongoing research, plan future research and conduct related professional activities. The research bases will continue the rigid quality control procedures which have proved so successful in the past, and upgrade these procedures as indicated. We will constantly monitor CCOP and member performance, not only by timely review of patient accrual, data sheets, pathology material, operative reports, and radiation therapy port films, but also by periodic, randomly-scheduled monitoring site visits. The research bases will work with investigators and members in preparing publications as well as presentations for national and regional meetings. We will make every effort to provide members with reasons to be proud of their participation in the National Cancer Program. Our focus, over this grant period, will be on the further expansion of our cancer control efforts to include high priority symptoms adversely affecting completion of cancer treatment as well as survivorship quality, cancer prevention, and screening. We will incorporate associated basic laboratory support, leading to scientifically rigorous translational research efforts. Lastly, we will strive to meld ourselves, with two other current cooperative oncology groups (CALGB and ACOSOG) to become one Alliance group to continue the efforts described in this current grant proposal.

Public Health Relevance

This project is very relevant to public health as cancer is such a large clinical problem leading to substantial disability and death. This program will define optimal means for controlling symptoms related to cancer and/or cancer therapy along with investigating methods to detect cancer early and prevent cancer. It will involve academic medical centers and also non-academic cancer clinical practice sites.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Dy, Grace K; Molina, Julian R; Qi, Yingwei et al. (2014) NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 9:1146-53
Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:
Beutler, Andreas S; Kulkarni, Amit A; Kanwar, Rahul et al. (2014) Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol 76:727-37
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Sha, Dan; Lee, Adam M; Shi, Qian et al. (2014) Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res 20:3319-27
Pachman, Deirdre R; Loprinzi, Charles L; Grothey, Axel et al. (2014) The search for treatments to reduce chemotherapy-induced peripheral neuropathy. J Clin Invest 124:72-4

Showing the most recent 10 out of 337 publications